皮膚糸状菌爪真菌症（DO）：米国（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 14
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Epidemiology 21
4.1 Risk Factors and Comorbidities 21
4.1.1 Poor peripheral circulation is greater in older men 22
4.1.2 Household contact with other DO patients increases risk of infection 2.5 times 22
4.1.3 Immunosuppression increases susceptibility to DO infections 23
4.1.4 Prevalence of dermatophytic onychomycosis is higher in diabetics than in non-diabetics 24
4.2 Global Trends 25
4.3 Forecast Methodology 26
4.3.1 Sources Used 26
4.3.2 Forecast Assumptions and Methods 26
4.3.3 Sources Not Used 27
4.4 Epidemiology Forecast (2012–2022) 28
4.4.1 Prevalent Cases of Dermatophytic Onychomycosis 28
4.4.2 Age-Specific Prevalent Cases of Dermatophytic Onychomycosis 29
4.4.3 Sex-Specific Prevalent Cases of Dermatophytic Onychomycosis 30
4.5 Discussion 31
4.5.1 Epidemiological Trends 31
4.5.2 Limitations of the Analysis 32
4.5.3 Strengths of the Analysis 32
5 Disease Management 33
5.1 Treatment Overview 33
5.1.1 Diagnosis 35
5.1.2 Clinical Practice 36
6 Competitive Assessment 41
6.1 Overview 41
6.2 Strategic Competitor Assessment 42
6.3 Product Profiles 43
6.3.1 Terbinafine 43
6.3.2 Itraconazole 47
6.3.3 Fluconazole 50
6.3.4 Ketoconazole 53
6.3.5 Griseofulvin 56
6.3.6 Ciclopirox 59
7 Opportunity and Unmet Need 62
7.1 Overview 62
7.2 Unmet Needs 63
7.2.1 Unmet Need: Efficacious Oral and Topical Treatments 63
7.2.2 Unmet Need: Clinical Safety 64
7.2.3 Unmet Need: Patient Awareness 65
7.2.4 Unmet Need: Shorter Treatment Duration 66
7.2.5 Unmet Need: Higher Treatment Rates 66
7.2.6 Unmet Need: Prescribing Guidelines 67
7.2.7 Unmet Need: Differential Diagnosis 67
7.3 Unmet Needs Gap Analysis 68
7.4 Opportunities 69
7.4.1 Opportunity: Decreased Frequency of Dosing 69
7.4.2 Opportunity: Combinatorial Approaches to Treatment 69
8 Clinical Pipeline Assessment 70
8.1 Overview 70
8.2 Clinical Trials by Phase and Trial Status 71
8.3 Promising Drugs in Clinical Development 72
8.3.1 Efinaconazole 74
8.3.2 Tavaborole 79
8.3.3 TDT-067 84
8.3.4 Luliconazole 89
8.3.5 Albaconazole 95
9 Current and Future Players 101
9.1 Overview 101
9.2 Trends in Corporate Strategy 103
9.3 Company Profiles 104
9.3.1 Valeant Pharmaceuticals International 104
9.3.2 Topica Pharmaceuticals 107
9.3.3 Anacor Pharmaceuticals 109
9.4 Late-Stage Competition 111
9.4.1 Celtic Pharmaceutical Holdings 111
9.4.2 Palau Pharma 112
9.5 Early-Stage Competition 113
9.5.1 Merck 113
9.5.2 Apricus Biosciences 113
10 Market Outlook 115
10.1 United States 115
10.1.1 Forecast 115
10.1.2 Key Events 119
10.1.3 Drivers and Barriers 120
11 Appendix 123
11.1 Bibliography 123
11.2 Abbreviations 134
11.3 Methodology 136
11.4 Forecasting Methodology 136
11.4.1 Diagnosed DO patients 137
11.4.2 Percent Drug-Treated Patients 137
11.4.3 Drugs Included in Each Therapeutic Class 137
11.4.4 Launch and Patent Expiry Dates 138
11.4.5 General Pricing Assumptions 138
11.4.6 Individual Drug Assumptions 138
11.4.7 Pricing of Pipeline Agents 141
11.5 Physicians and Specialists Included in this Study 142
11.6 About the Authors 143
11.6.1 Author 143
11.6.2 Reviewer 143
11.6.3 Epidemiologist 144
11.6.4 Global Head of Healthcare 144
11.7 About GlobalData 145
11.8 Disclaimer 145